These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30652926)

  • 1. Canakinumab for the treatment of hyperimmunoglobulin D syndrome.
    Sánchez-Manubens J; Iglesias E; Anton J
    Expert Rev Clin Immunol; 2019 Mar; 15(3):215-220. PubMed ID: 30652926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of canakinumab in hyperimmunoglobulin D syndrome.
    Ozdemir Isik O; Karadag DT; Tekeoglu S; Yazici A; Cefle K; Cefle A
    Int J Rheum Dis; 2024 Jan; 27(1):e14857. PubMed ID: 37578023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States.
    Hur P; Lomax KG; Ionescu-Ittu R; Manceur AM; Xie J; Cammarota J; Gautam R; Sanghera N; Kim N; Grom AA
    Pediatr Rheumatol Online J; 2021 Sep; 19(1):143. PubMed ID: 34521444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome.
    Shendi HM; Devlin LA; Edgar JD
    J Clin Rheumatol; 2014 Mar; 20(2):103-5. PubMed ID: 24561416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-demand anakinra treatment is effective in mevalonate kinase deficiency.
    Bodar EJ; Kuijk LM; Drenth JP; van der Meer JW; Simon A; Frenkel J
    Ann Rheum Dis; 2011 Dec; 70(12):2155-8. PubMed ID: 21859689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent macrophage activation syndrome due to hyperimmunoglobulin D syndrome: a case-based review.
    Gezgin Yıldırım D; Yıldız Yıldırım Ç; Karaçayır N; Esmeray Şenol P; Sunar Yayla EN; Bakkaloğlu SA
    Clin Rheumatol; 2023 Jan; 42(1):277-283. PubMed ID: 36149537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience.
    Kostjukovits S; Kalliokoski L; Antila K; Korppi M
    Eur J Pediatr; 2015 Jun; 174(6):707-14. PubMed ID: 25721923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome.
    Kuemmerle-Deschner JB; Gautam R; George AT; Raza S; Lomax KG; Hur P
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32723831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation.
    Normand S; Massonnet B; Delwail A; Favot L; Cuisset L; Grateau G; Morel F; Silvain C; Lecron JC
    Eur Cytokine Netw; 2009 Sep; 20(3):101-7. PubMed ID: 19825518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mevalonate kinase deficiency].
    Galeotti C
    Rev Prat; 2023 Oct; 73(8):850-854. PubMed ID: 38354005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.
    Kuemmerle-Deschner JB; Kallinich T; Henes J; Kortus-Götze B; Oommen PT; Rech J; Krickau T; Weller-Heinemann F; Horneff G; Janda A; Foeldvari I; Schuetz C; Dressler F; Borte M; Hufnagel M; Meier F; Fiene M; Andreica I; Weber-Arden J; Blank N
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38360038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mevalonate kinase deficiency in 2016].
    Galeotti C; Georgin-Lavialle S; Sarrabay G; Touitou I; Koné-Paut I
    Rev Med Interne; 2018 Apr; 39(4):265-270. PubMed ID: 27659743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.
    Ozen S; Kuemmerle-Deschner JB; Cimaz R; Livneh A; Quartier P; Kone-Paut I; Zeft A; Spalding S; Gul A; Hentgen V; Savic S; Foeldvari I; Frenkel J; Cantarini L; Patel D; Weiss J; Marinsek N; Degun R; Lomax KG; Lachmann HJ
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):578-586. PubMed ID: 27723279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome.
    van der Hilst JCH; Bodar EJ; Barron KS; Frenkel J; Drenth JPH; van der Meer JWM; Simon A;
    Medicine (Baltimore); 2008 Nov; 87(6):301-310. PubMed ID: 19011501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperimmunoglobulinemia D syndrome with recurrent perianal abscess successfully treated with canakinumab.
    Miray Kisla Ekinci R; Balcı S; Bisgin A; Tumgor G; Dogruel D; Yilmaz M
    Scott Med J; 2019 Aug; 64(3):103-107. PubMed ID: 30862258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative.
    Hansmann S; Lainka E; Horneff G; Holzinger D; Rieber N; Jansson AF; Rösen-Wolff A; Erbis G; Prelog M; Brunner J; Benseler SM; Kuemmerle-Deschner JB
    Pediatr Rheumatol Online J; 2020 Feb; 18(1):17. PubMed ID: 32066461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances in the understanding and treatment of mevalonate kinase deficiency.
    Esposito S; Ascolese B; Senatore L; Bosis S; Verrecchia E; Cantarini L; Rigante D
    Int J Immunopathol Pharmacol; 2014; 27(4):491-8. PubMed ID: 25572728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra.
    Peciuliene S; Burnyte B; Gudaitiene R; Rusoniene S; Drazdiene N; Liubsys A; Utkus A
    Pediatr Rheumatol Online J; 2016 Mar; 14(1):19. PubMed ID: 27012807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan.
    Hosono K; Matsumoto K; Shimbo M; Tsumiyama I; Kato C
    Mod Rheumatol; 2023 Mar; 33(2):381-391. PubMed ID: 35575279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.